A study found that regulating ROS or inhibiting fibroblasts growth factor receptor 1 (FGFR1) signaling could abrogate the immunosuppression mediated by PD-L1, improving the efficacy of immunotherapy in KRAS-mutant cancers [142]. The gene discussed is KRAS; the disease is cancer.